#None #Financial Performance #2025 results #Bausch Health

Bausch Health Announces 2025 Financial Results

Bausch Health Companies Inc. has recently revealed its financial results for the fourth quarter and the entire year of 2025, showcasing significant improvements in revenue and operational metrics. For the fourth quarter, the consolidated revenues reached $2.80 billion, indicating a 9% increase compared to the previous year. When considering organic growth, the revenue rose by 6%. The total consolidated revenues for 2025 amounted to $10.27 billion, marking a 7% growth compared to 2024, with an organic increase of 5%.

Financial Performance Breakdown

During the fourth quarter, Bausch Health generated a net loss of $112 million. However, for the full year, the company reported a net income of $157 million, indicating a significant turnaround. The adjusted EBITDA for the quarter stood at $1.05 billion, reflecting a 13% increase, while the yearly adjusted EBITDA reached $3.54 billion, up by 7%. This marks the eleventh consecutive quarter of growth in revenue and adjusted EBITDA for Bausch Health, excluding contributions from Bausch + Lomb.

CEO Thomas J. Appio emphasized that these results highlight the company’s commitment to operational excellence and strategic growth initiatives, evidenced by the acquisition of Shibo's full-service aesthetics distribution business in China at the end of 2025. This acquisition not only broadens Bausch Health’s geographical reach but also potentiate its ability to meet the growing demand in the aesthetics market.

Revenue Segmentation

The financial performance varied across different segments:

• - Bausch Health excluding Bausch + Lomb: Revenues increased to $1.39 billion, a growth of 9%, while Salix, International, and Diversified Products segments also reported positive growth, contributing significantly to the firm’s overall performance. The Solta Medical segment experienced a minor decline, while the Bausch + Lomb segment recorded $1.41 billion in revenue, up 10%.

Strategic Initiatives and Market Expansion

The financial results for 2025 are further complemented by a proactive debt exchange offer worth $1.7 billion executed in the fourth quarter, part of a larger refinancing strategy totaling $9.6 billion for the entire year. This refinancing effort aims to optimize debt maturities and financial position going forward, demonstrating Bausch Health's agility in managing its capital structure.

Adjusted cash flow from operations for the fourth quarter stood at $362 million, totaling $1.2 billion for the year. These numbers reflect improved efficiencies and cash management practices, which are crucial for sustaining future growth initiatives.

Challenges and Future Outlook

However, Bausch Health also faced challenges in the first quarter, especially regarding a significant $145 million goodwill impairment related to its Generics business unit. The company continues to address these challenges while focusing on operational improvements and maintaining a solid financial framework.

Looking ahead, Bausch Health provided financial guidance for 2026, with projected revenues of $10.625 to $10.875 billion and adjusted EBITDA between $3.875 to $4 billion. The company remains steadfast in its goal to expand its portfolio through strategic acquisitions, innovations in its product lines, and the pursuit of operational excellence.

Conclusion

Overall, Bausch Health's 2025 financial results underline not only its resilience amidst market challenges but also a solid foundation for future growth. The strategic initiatives outlined in these results position the company to capitalize on emerging opportunities in the healthcare landscape while addressing ongoing market demands. As Bausch Health moves into 2026, it continues to build toward a promising future, committed to enhancing healthcare outcomes on a global scale.